Professor Etienne Sokal is founder, Senior Scientific & Medical Advisor, Chairman of the Medical & Scientific Advisory Board of Promethera Biosciences. Since 2000, his hepatocyte and stem cell tissue bank has pioneered first hepatocyte, and then liver stem cell, transplantation for the treatment of inborn errors of liver metabolism and acquired liver diseases. The translational research led to the discovery and clinical translation of the regenerative liver stem cell program. From this, Professor Sokal founded Promethera Biosciences in 2009 with the University Technology Transfer office, which is now the world leader in regenerative medicine of the liver using liver derived stem cells and antibodies. Promethera is currently in clinical trial phase in different European countries.
Professor Sokal is also Head of the Pediatric Gastroenterology and Hepatology service and director of the liver tissue and stem cell bank at Cliniques Universitaires St Luc in Brussels. He is also a professor at the faculty of medicine and director of the liver & cell therapy research unit at the Experimental & Clinical Research Institute, Université Catholique de Louvain, Belgium.
Professor Sokal is a member of the Royal Academy of Medicine. His liver unit in Brussels is an international referral center for pediatric liver diseases and liver transplantation, with more than 1000 pediatric liver transplants performed since 1984.
His clinical & lab research has focused on congenital and acquired liver diseases, inborn metabolic diseases, viral hepatitis, NASH, liver transplantation and stem cells. His pioneering PhD thesis work in 1993 greatly enhanced the understanding of liver metabolic zonation and its adaptive changes with extracellular matrix remodeling during cirrhosis development.
Professor Sokal is a member of various stem cell, liver and GI scientific societies and is a regular speaker at national and international conferences. He has published over 320 peer-reviewed articles, with >18000 citations (h-index 745, Google scholar).